Brainomix has announced that results from what it claims is the largest prospective study of stroke artificial intelligence (AI) software were presented yesterday at the European Stroke Organisation Conference (ESOC; 15–17 May, Basel, Switzerland), showing that the implementation of Brainomix 360 Stroke was associated with a 50% greater increase in the number of patients receiving mechanical thrombectomy.
The study stemmed from an independent evaluation of Brainomix 360 Stroke commissioned by the UK government across five stroke networks, over the course of three years, to determine the real-world impact of AI technology. The analysis—led by Health Innovation (HIN) Oxford & Thames Valley—was conducted using patient-level and site-level data from the Sentinel Stroke National Audit Programme (SSNAP), including more than 83,000 individual stroke patient data from the 26 sites participating in the evaluation.
When compared against site-level data from 73 UK hospitals not included in the AI award, the results showed the rate of thrombectomy rose by 115% at evaluation sites—50% more than the increase observed at non-evaluation sites (65%). In addition, the results suggested that Brainomix 360 Stroke was associated with an improvement in the speed of treatment by 49 minutes.
Kiruba Nagaratnam (Royal Berkshire NHS Foundation Trust, Reading, UK) was the lead author of the study and presented results on Wednesday afternoon at ESOC 2024.
“This study is the largest real-world evaluation of stroke AI software, with more than 80,000 patients assessed over a three-year period,” Nagaratnam said. “The results showed that the introduction of Brainomix 360 Stroke reduced the door-in-door-out (DIDO) time by 49 minutes—and, notably, was associated with a significant increase in the number of patients receiving mechanical thrombectomy. These are very powerful results and they show that the large-scale implementation of the Brainomix software as a component of a collaborative model of care in stroke networks is feasible and is associated with increasing access to mechanical thrombectomy treatment.”
“We are delighted to see the dramatic increase in stroke treatment numbers and improved treatment times across multiple stroke networks in England following the implementation of Brainomix 360 Stroke,” added George Harston (Oxford University Hospitals NHS Foundation Trust, Oxford, UK), chief medical and innovation officer at Brainomix. “This is the largest study of stroke AI software ever undertaken, and the results not only validate the generalisability of the findings we have seen in single-site studies, but also reflect the comprehensive nature of the Brainomix 360 Stroke platform, which uniquely delivers value to both primary and comprehensive stroke centres.
“We estimate that, if the same increase on thrombectomy had been seen across the whole NHS in England, in a single calendar year, the cost savings to the UK economy would be around £30 million. We would like to thank the Oxford HIN and NHS Accelerated Access Collaborative (AAC) for their robust evaluation and support, and all the hospital teams and patients who collaborated in this landmark research study.”
This latest study builds on a growing body of evidence validating the impact of Brainomix’s stroke AI imaging platform, including a study published earlier this year in Frontiers in Neurology, which showed that the implementation of Brainomix 360 Stroke at the Royal Berkshire Hospital (Reading, UK) improved patient outcomes, trebling the number of stroke patients achieving functional independence from 16% to 48%.
